Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Avant Diagnostics, Inc | americanliberty_8k.htm |
| EX-99.02 - PRESS RELEASE FOR SHARE EXCHANGE - Avant Diagnostics, Inc | amerliberty_ex9902.htm |
| EX-99.03 - AMENDMENT #1 TO LETTER OF INTENT - Avant Diagnostics, Inc | amerliberty_ex9903.htm |
| EX-99.01 - UNAUDITED PRO FORMA FINANCIAL STATEMENTS - Avant Diagnostics, Inc | amerliberty_ex9901.htm |
Exhibit 99.04
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Avant Diagnostics, Inc.,
Scottsdale, AZ
We have audited the accompanying balance sheets of Avant Diagnostics, Inc. as of September 30, 2014 and 2013, and the related statements of operations, comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Avant Diagnostics, Inc. as of September 30, 2014 and 2013, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.
/s/LBB & Associates Ltd., LLP
LBB & Associates Ltd., LLP
Houston, Texas
December 12, 2014
| 1 |
Avant Diagnostics, Inc.
BALANCE SHEETS
| September 30, | ||||||||
| 2014 | 2013 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,000 | $ | 43,000 | ||||
| Marketable securities | 1,600,000 | – | ||||||
| Total current assets | 1,606,000 | 43,000 | ||||||
| License, net | 1,693,000 | 143,000 | ||||||
| Total assets | $ | 3,299,000 | $ | 186,000 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 166,000 | $ | 246,000 | ||||
| Total Liabilities | 166,000 | 246,000 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity (deficit): | ||||||||
| Preferred stock, $0.001 par value per share; 20,000,000 shares authorized | ||||||||
| Series B preferred stock, $0.001 par value; 3,000 issued and outstanding as of September 30, 2014 and 2013, respectively | – | – | ||||||
| Common stock, $0.001 par value; 480,000,000 shares authorized; 71,655,800 and 44,805,800 shares issued and outstanding as of September 30, 2014 and 2013, respectively | 72,000 | 45,000 | ||||||
| Additional paid-in capital | 9,932,000 | 5,841,000 | ||||||
| Accumulated other comprehensive income (loss) | (400,000 | ) | – | |||||
| Accumulated deficit | (6,471,000 | ) | (5,946,000 | ) | ||||
| Total stockholders' equity (deficit) | 3,133,000 | (60,000 | ) | |||||
| Total liabilities and stockholders' equity (deficit) | $ | 3,299,000 | $ | 186,000 | ||||
The accompanying notes are an integral part of these financial statements.
| 2 |
Avant Diagnostics, Inc.
STATEMENTS OF OPERATIONS
| Year Ended September 30, | ||||||||
| 2014 | 2013 | |||||||
| OPERATING EXPENSES: | ||||||||
| Selling, general and administrative | $ | 525,000 | $ | 4,145,000 | ||||
| Total operating expenses | 525,000 | 4,145,000 | ||||||
| Loss from operations before income taxes | (525,000 | ) | (4,145,000 | ) | ||||
| Income tax (benefit) provision | – | – | ||||||
| Net loss | $ | (525,000 | ) | $ | (4,145,000 | ) | ||
| Basic and diluted net loss per common share | $ | (0.01 | ) | $ | (0.10 | ) | ||
| Shares used in computing basic and diluted net loss per common share | 50,172,000 | 40,858,000 | ||||||
The accompanying notes are an integral part of these financial statements.
| 3 |
Avant Diagnostics, Inc.
STATEMENTS OF COMPREHENSIVE LOSS
| Year Ended September 30, | ||||||||
| 2014 | 2013 | |||||||
| Net loss | $ | (525,000 | ) | $ | (4,145,000 | ) | ||
| Available for sale securities: | ||||||||
| Unrealized change in available-for-sale securities | (400,000 | ) | – | |||||
| Net change in unrealized gains (losses) on available-for-sale securities, net of tax | (400,000 | ) | – | |||||
| Comprehensive income (loss) | $ | (925,000 | ) | $ | (4,145,000 | ) | ||
The accompanying notes are an integral part of these financial statements.
| 4 |
Avant Diagnostics, Inc.
STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
Years Ended September 30, 2014
| Preferred Stock | Common Stock | Additional Paid-in | Accumulated Other Comprehensive | Accumulated | ||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Total | |||||||||||||||||||||||||
| Balance as of September 30, 2012 | 3,000 | $ | – | 33,260,000 | $ | 33,000 | $ | 1,348,000 | $ | – | $ | (1,801,000 | ) | $ | (420,000 | ) | ||||||||||||||||
| Share-based compensation | – | – | 8,250,000 | 8,000 | 1,642,000 | – | – | 1,650,000 | ||||||||||||||||||||||||
| Stock issued for cash | – | – | 796,000 | 1,000 | 168,000 | – | – | 169,000 | ||||||||||||||||||||||||
| Stock issued for settlement liabilities | – | – | 2,500,000 | 3,000 | 700,000 | – | – | 703,000 | ||||||||||||||||||||||||
| Options issued for services | – | – | – | – | 1,983,000 | – | 1,983,000 | |||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | (4,145,000 | ) | (4,145,000 | ) | ||||||||||||||||||||||
| Balance as of September 30, 2013 | 3,000 | – | 44,806,000 | 45,000 | 5,841,000 | – | (5,946,000 | ) | (60,000 | ) | ||||||||||||||||||||||
| Share-based compensation | – | – | 6,050,000 | 6,000 | 296,000 | – | – | 302,000 | ||||||||||||||||||||||||
| Stock issued for cash | – | – | 800,000 | 1,000 | 89,000 | – | – | 90,000 | ||||||||||||||||||||||||
| Stock issued for license | – | – | 10,000,000 | 10,000 | 1,540,000 | – | – | 1,550,000 | ||||||||||||||||||||||||
| Stock issued in exchange for available-for-sale securities | – | – | 10,000,000 | 10,000 | 1,990,000 | – | – | 2,000,000 | ||||||||||||||||||||||||
| Warrants issued for services | – | – | – | – | 98,000 | – | – | 98,000 | ||||||||||||||||||||||||
| Capital contribution | – | – | – | – | 78,000 | – | – | 78,000 | ||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | (525,000 | ) | (525,000 | ) | ||||||||||||||||||||||
| Unrealized loss on available-for-sale securities | – | – | – | – | – | (400,000 | ) | – | (400,000 | ) | ||||||||||||||||||||||
| Balance as of September 30, 2014 | 3,000 | $ | – | 71,656,000 | $ | 72,000 | $ | 9,932,000 | $ | (400,000 | ) | $ | (6,471,000 | ) | $ | 3,133,000 | ||||||||||||||||
The accompanying notes are an integral part of these financial statements.
| 5 |
Avant Diagnostics, Inc.
STATEMENTS OF CASH FLOWS
| Year Ended September 30, | ||||||||
| 2014 | 2013 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (525,000 | ) | $ | (4,145,000 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Share-based compensation | 302,000 | 1,650,000 | ||||||
| Warrant expense | 98,000 | – | ||||||
| Stock option expense | – | 1,983,000 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts payable and accrued liabilities | (2,000 | ) | 363,000 | |||||
| Net cash used by operating activities | (127,000 | ) | (149,000 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Investment in marketable securities | – | – | ||||||
| Net cash provided by (used in) investing activities | – | – | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Common stock issued for cash | 90,000 | 169,000 | ||||||
| Net cash provided by financing activities | 90,000 | 169,000 | ||||||
| Net (decrease) increase in cash and cash equivalents | (37,000 | ) | 20,000 | |||||
| Cash and cash equivalents at beginning of period | 43,000 | 23,000 | ||||||
| Cash and cash equivalents at end of period | $ | 6,000 | $ | 43,000 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Interest paid | $ | – | $ | – | ||||
| Taxes paid | $ | – | $ | – | ||||
| Supplemental non-cash disclosures: | ||||||||
| Common stock for available-for-sale securities | $ | 2,000,000 | $ | – | ||||
| Common stock for license | $ | 1,550,000 | $ | – | ||||
| Unrealized loss on available-for-sale securities | $ | 400,000 | $ | – | ||||
| Capital contribution by Arrayit Corporation | $ | 78,000 | $ | – | ||||
| Common stock for accounts payable and accrued expenses | $ | – | $ | 703,000 | ||||
The accompanying notes are an integral part of these financial statements.
| 6 |
Avant Diagnostics, Inc.
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2014 AND 2013
NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION
Avant Diagnostics, Inc., ("Avant" or the "Company") is a Nevada corporation established in 2009, as a diagnostic company that focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. In January 2013, the Company effected a name change, Avant was originally named Arrayit Diagnostics, Inc. (“AD”) which was formed as a majority owned subsidiary of Arrayit Corporation (“Arrayit”) through a technology transfer in July 2009. The Company’s premier product is OvaDx®, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. This test is expected to be approved by the U.S. Food and Drug Administration (FDA) as the first pre-symptomatic screening test for ovarian cancer in the United States, detecting all types and all stages of ovarian cancer with high sensitivity and specificity.
BASIS OF PRESENTATION
The accompanying financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
USE OF ESTIMATES
The accompanying financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) which require management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates.
MARKETABLE SECURITIES
The Company's investments consist of available for sale securities. The Company's investments are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders' equity. The fair values of securities are based on quoted market prices.
INTANGIBLE ASSETS
Indefinite-lived intangible assets including licenses are reviewed for impairment when facts or circumstances suggest that the carrying value of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. For the years ended September 30, 2014 and 2013, no impairment charges were recognized.
| 7 |
SHARE-BASED COMPENSATION
The Company estimates the fair value of its option grants and shares sold under its Employee Stock Purchase Plan using the Black-Scholes-Merton ("BSM") option pricing model. This model requires the use of certain estimates and assumptions such as the expected term of options, estimated forfeitures, expected volatility of the Company's stock price, expected dividends and the risk-free interest rate at the grant date to determine the fair value of stock options.
COMPREHENSIVE INCOME (LOSS)
Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes unrealized gains and losses on the Company's available-for-sale securities that are excluded from net loss. Total comprehensive income (loss) has been disclosed in the Company's Consolidated Statements of Comprehensive Loss.
As of September 30, 2014 and 2013, the components of accumulated other comprehensive income, net of tax, are as follows:
| September 30, | ||||||||
| 2014 | 2013 | |||||||
| Unrealized loss on available-for-sale securities | $ | (400,000 | ) | $ | – | |||
| Accumulated other comprehensive income | $ | (400,000 | ) | $ | – | |||
NET LOSS PER COMMON SHARE
Basic net loss per common share is calculated using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive common stock options and warrants issued to employees and officers.
The potentially dilutive securities excluded from diluted earnings per common share on an actual outstanding basis, were as follows:
| September 30, | ||||||||
| 2014 | 2013 | |||||||
| Employee stock options and warrants | 12,000,000 | 10,000,000 | ||||||
| Total | 12,000,000 | 10,000,000 | ||||||
| 8 |
RECENT ACCOUNTING PRONOUNCEMENTS
In the February 2013, the FASB issued Accounting Standards Update No. 2013-02 Comprehensive Income (Topic 220); Reporting Amounts Reclassified out of Accumulated Other Comprehensive Income, which requires filers to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net loss. The Company adopted this accounting standard during the first quarter of 2013.
NOTE 2 –FAIR VALUE MEASUREMENTS
Fair Value
The carrying value of cash and cash equivalents, available-for-sale securities, accounts payable and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
| · | Level one — Quoted market prices in active markets for identical assets or liabilities; |
| · | Level two — Inputs other than level one inputs that are either directly or indirectly observable; and |
| · | Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. |
Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter
As of September 30, 2014 and 2013, the Company had no financial assets or liabilities requiring Level 2 or 3 classification, including those that have unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets and liabilities. The carrying values for cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate their fair value due to their short maturities.
NOTE 3 – FINANCIAL INSTRUMENTS
Investments in Equity Securities
The fair values of the Company’s marketable securities are based on quoted market prices and are included in the accompanying Consolidated Balance under Total Current Assets as Available-for sale securities.
As of September 30, 2014 the Company’s available-for-sale securities consisted of 10,000,000 shares of Arrayit Corporation (OTCBB:ARYC) acquired in August 2014 in exchange for the issuance of 10,000,000 common shares of the Company. Both the Arrayit and the Company’s shares are restricted under rule 144. The shares were exchanged pursuant to a Agreement and Plan of Reorganization with Arrayit in August 2014.
The Arrayit shares were quoted at $0.20 per share on the date of issuance and at $0.16 as of September 30, 2014. The Company recorded a $400,000 loss to other comprehensive income as of September 30, 2014.
| 9 |
NOTE 4 – LICENSE AGREEMENT
The Company's intangible assets consists of technology enhancements and licensing payments for its worldwide exclusive licensed rights to OvaDx®, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The intravenous of “finger stick” blood sample detects early and late stage ovarian cancer of all sub-types. Since the test is performed in a digital platform and compared against known bio-markers, it gives a definitive “yes or no” answer. This test is expected to be approved by the U.S. Food and Drug Administration (FDA) as the first pre-symptomatic screening test for ovarian cancer in the United States, detecting all types and all stages of ovarian cancer with high sensitivity and specificity.
In December 2009, the Company entered into a worldwide licensing agreement and sponsored research agreement with Arrayit and Wayne State University (“WSU”) in Detroit, Michigan, for the continued research and development of a protein microarray based diagnostic test for the early detection of ovarian cancer. WSU’s research involving ovarian cancer has been focused on the specific expression of genes associated with ovarian cancer. For more than ten years, WSU has used Arrayit's microarray technology to help identify key biomarkers using a novel process that has allowed them to isolate biomarkers unique to ovarian cancer. As a result, Arrayit has been able to build on this approach and is now in the late stage development phase of a simple blood test for the early detection of ovarian cancer that uses approximately 100 unique proteomic biomarkers in a microarray-based serologic detection of ovarian cancer markers that accumulate in the bloodstream as a result of the body’s natural immune response to developing ovarian tumors. The approach is based on the premise that cancer is a complex illness whose evolution over time is determined by a complex set of factors that depend both on the etiology of the illness and its interaction with the immune system of the specific patient. The main hypothesis is that any single marker will not have the ability to capture the complexities of this interaction, whereas a broad set of markers has a much better potential to do so. This approach allows ovarian tumors to be detected at stage I of the illness, up to five years before symptoms occur in patients, which allows early medical intervention and a marked improvement in prognosis.
WSU shall have the right to terminate the agreement if it reasonable determines that Licensee is not diligently utilizing the Licensed Patents or the license agreement will expire as the patents expire.
Exclusive services agreement entered into by Arrayit and the Company. The Company agrees that, during the term of the agreement, Arrayit will be the exclusive supplier of the diagnostic product. The initial term is 5 years, with the election to extend the agreement for an additional 5 years or if no election made the agreement will automatically renew for successive two year periods. The term has been extended through September 2019. In August 2014, the Company and Arrayit agreed that upon the sale or license of OvaDx, the exclusive services agreement would be terminated at no-cost if required by a purchaser or licensee.
| 10 |
NOTE 4 – LICENSE AGREEMENT – (Continued)
As of September 30, 2014 and 2013, the carrying value of the rights to OvaDx® and payments to WSU was $1,693,000 and $143,000, respectively consisting of enhancements to the original initial rights licensed assigned to the Company resulting from the technology transfer from Arrayit as well as licensing payments made to WSU. The Company paid for these enhancements by the issuance of 10,000,000 common shares to Arrayit in August 2014 and as well as cash payments to WSU during 2014 and 2013. It will be assessed over time for changes in valuation. The Company is not amortizing the value of the license. The Company will amortize the license upon FDA approval. The Company evaluated the carrying value of the license and determined that no impairment exists; therefore, no impairment loss was recognized at September 30, 2014 and 2013, respectively.
Wayne State University License Agreement
Under the terms of the license agreement with Wayne State University (“WSU”) the Company is obligated to make a one-time payment of $125,000 to WSU within 30 days after the approval of the first licensed product by the FDA or another comparable agency, and is obligated to make royalty payments of up to 5% of the net revenues of the licensed products on a quarterly basis or a minimum royalty payments of $25,000 for 2015, $50,000 for 2017, $150,000 for 2019 and $300,000 each year thereafter.
NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities as of September 30, 2014 and 2013 consist of the following:
| September 30, | ||||||||
| 2014 | 2013 | |||||||
| Accounts payable and accrued liabilities | $ | 114,000 | $ | 222,000 | ||||
| Due to officers | 52,000 | 24,000 | ||||||
| Total | $ | 166,000 | $ | 246,000 | ||||
In March 2014, Arrayit issued 500,000 shares of its common stock to settle approximately $78,000 of accrued liabilities. We recorded the settlement as a contribution of capital.
During 2013, we issued 2,500,000 shares of our common stock to settle liabilities of approximately $703,000 as of September 30, 2012 to our former Chief Executive Officer.
| 11 |
NOTE 6 – COMMITMENTS
Lease of Corporate office
As of September 30, 2014 we lease corporate office space under a month-to-month operating lease at 8561 E. Anderson Drive, #104, Scottsdale, AZ 85255 for $200 per month from an entity controlled by the Company’s COO/CFO.
NOTE 7 – STOCKHOLDERS' EQUITY AND SHARE-BASED COMPENSATION EXPENSE
Preferred Stock
The total number of authorized shares of the Company’s preferred stock is 20,000,000 shares, $0.001 par value per share. The total number of designated shares of the Company’s Series B Preferred Stock is 3,000. As of September 30, 2014 and 2013, there were 3,000 shares Series B Preferred Shares issued and outstanding.
Holders of outstanding shares of the Company’s Series B Preferred are not entitled to receive dividends and have no liquidation preference and no redemption privileges. The shares of the Series B Preferred shall always constitute two-thirds voting power.
Concurrent with the consummation of the proposed merger, see subsequent events, the Series B Preferred Stock outstanding will be retired at no cost to the Company.
Common Stock
During the year ended September 30, 2013, the Company issued 796,000 shares of our common stock in exchange for $169,000 and 8,250,000 shares of our common stock in exchange for consulting services valued at $1,650,000 and 2,500,000 shares of our common stock to settle accounts payable and accrued liabilities valued at $703,000.
During the year ended September 30, 2014, the Company issued 800,000 shares of our common stock for $90,000 and 6,050,000 shares of our common stock for consulting services valued at $302,000 and 10,000,000 shares of our common stock for intellectual property valued at $1,550,000 and 10,000,000 shares of our common stock exchange for 10,000,000 shares of Arrayit Corporation common stock valued at $2,000,000.
During October and November 2014, the Company sold 2,733,334 shares of common stock for $350,000.
Stock Options and Warrants
In December 2012, the Company issued a total of 10,000,000 options or 5,000,000 options for one share of common stock each to its officers exercisable immediately at $0.05 per share according to the officer’s employment contracts. In August 2013, in conjunction with certain services provided by Issuers Capital Advisors (“ICA”, an entity controlled by the Company’s officers) we issued 2,000,000 warrants to ICA to purchase common stock immediately exercisable at $0.05 per share.
| 12 |
NOTE 7 – STOCKHOLDERS' EQUITY AND SHARE-BASED COMPENSATION EXPENSE – (Continued)
The fair value of stock options and warrants issued was estimated at the respective dates of grant using the BSM option pricing model with the following weighted-average assumptions:
| 2014 | 2013 | |||||||
| Risk free interest rate | .1% | .1% | ||||||
| Expected dividend yield | –% | –% | ||||||
| Expected volatility | 25% | 25% | ||||||
| Expected option term (in years) | 10 | 10 | ||||||
Based on the above pricing assumptions the value of the options issued in December 2012 was estimated at $1,983,000 and charged to consulting expense for the year ended September 30, 2013. The warrants issued in August 2014 were estimated at $98,000 and charged to consulting expense for the year ended September 30, 2014.
Stock option activity for the years ended September 30, 2014 and 2013 are summarized as follows:
| Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (in Years) | Grant Date Fair Value | |||||||||||||
| Outstanding as of September 30, 2013 | 10,000,000 | $ | 0.05 | 7.21 | $ | 1,983,000 | ||||||||||
| Options granted | – | – | – | – | ||||||||||||
| Options exercised | – | – | – | – | ||||||||||||
| Options cancelled/forfeited/expired | – | – | – | – | ||||||||||||
| Outstanding as of September 30, 2014 | 10,000,000 | $ | 0.05 | 6.21 | $ | 1,983,000 | ||||||||||
| Vested as of September 30, 2014 | 10,000,000 | $ | 0.05 | 6.21 | $ | 1,983,000 | ||||||||||
| Exercisable as of September 30, 2014 | 10,000,000 | $ | 0.05 | 6.21 | $ | 1,983,000 | ||||||||||
The following tables set forth summarized warrants that are issued, outstanding and exercisable for the years ended September 30, 2014 and 2013:
| Weighted Average Exercise Price | Expiration Date | September 30, 2013 | Issued | Exercised | Expired | September 30, 2014 | ||||||||||||||||||
| $ | 0.05 | Aug-24 | – | 2,000,000 | – | – | 2,000,000 | |||||||||||||||||
| Total Warrants | – | 2,000,000 | – | – | 2,000,000 | |||||||||||||||||||
NOTE 8 – LEGAL PROCEEDINGS
On January 13, 2014, Plaintiff Tamarin Lindenberg sued Arrayit Corporation, the Company, John Howell, Steven Scott and Gregg Linn in Civil Action No. L7698-13. Plaintiff alleged violations of the New Jersey Conscientious Employee Protection Act NJSA 34:19-1 to NJSA 34:19-8 (“CEPA”), breach of contract, breach of covenant of good faith and fair dealing, economic duress and intentional infliction of emotional distress. On August 6, 2014 the District Court dismissed Plaintiff’s complaint against Arrayit Corporation for failure to state a claim upon which relief may be granted and against John Howell for lack of jurisdiction. Avant and its Officers remain a defendant in the action. The Company and its Officers have mounted a vigorous defense against these claims and believe they are without legal merit.
| 13 |
NOTE 9 – INCOME TAXES
The provision for refundable federal income tax consists of the following for the periods ending:
| Year Ended September 30, | ||||||||
| 2014 | 2013 | |||||||
| Income tax expense (benefit) at the rate of 34% | $ | (210,000 | ) | $ | (1,658,000 | ) | ||
| Stock-based compensation | 136,000 | 1,235,000 | ||||||
| Valuation difference | 74,000 | 423,000 | ||||||
| Net benefit | $ | – | $ | – | ||||
| September 30, | ||||||||
| 2014 | 2013 | |||||||
| The tax effects of temporary differences that give rise to significant portions of the deferred tax assets as of September 30, 2014 and 2013 are presented below: | ||||||||
| Deferred tax asset: | ||||||||
| Stock-based compensation | $ | 1,371,000 | $ | 1,235,000 | ||||
| Net operating loss carryover | 234,000 | 220,000 | ||||||
| Less valuation allowance | (1,605,000 | ) | (1,455,000 | ) | ||||
| Net deferred tax asset | $ | – | $ | – | ||||
The Company has historical losses and an accumulated deficit of $6,471,000 as of September 30, 2014 and has not filed either Federal or State income tax returns since its inception. The Company has determined that a valuation allowance of $1,605,000 as of September 30, 2014, is necessary to reduce the deferred tax assets to the amount that will more than likely than not be realized. The change in valuation allowance for 2014 was approximately $150,000. As of September 30, 2014, the Company has net operating loss carry-forwards of $688,000, which is available to offset future federal taxable income, if any, with expiration beginning 2029 and ending 2034.
| 14 |
NOTE 10 – RELATED PARTY TRANSACTIONS
In August 2013, the Company issued 2,000,000 warrants for the exercise of one share of the Company’s common stock at $0.05 per share to Investors’ Capital Advisors (“ICA”) for certain services provided by ICA. ICA is controlled by the Company’s officers.
As of September 30, 2014 we lease corporate office space under a month-to-month operating lease at 8561 E. Anderson Drive, #105, Scottsdale, AZ 85255 for $200 per month from an entity controlled by the Company’s COO/CFO.
Under the terms of their employment contracts the company’s officers are reimbursed for health insurance coverage and a car allowance of $3,000 and $1,500 per month each beginning in December 2012. As of September 30, 2014 and 2013, the amounts accrued and still owing under these provisions was $52,000 and $24,000 (aggregate) respectively which is included in accounts payable and accrued liabilities.
During 2013, we issued 2,500,000 shares of our common stock to settle liabilities of approximately $703,000 as of September 30, 2012 owed to our former Chief Executive Officer.
NOTE 11 – SUBSEQUENT EVENTS
During October and November 2014, the Company sold 2,733,334 shares of common stock for $350,000.
The Company signed a letter of intent to merge with American Liberty Petroleum Corporation. Upon consummation of the merger, management will enter into a voting agreement with Arrayit to maintain voting control as the Series B Preferred Stock outstanding will be retired by the Company.
As part of a settlement with the Company, Arrayit will dividend out 10,000,000 shares of the Company after the merger and we have agreed to register those shares. If we are not successful in becoming publically traded by August 2015, we will sell the OvaDx® rights to Arrayit for 10,000,000 common shares of Arrayit.
| 15 |